Chief Executive Officer - Before joining Mirnext, Heico Breek held senior management positions in both Europe and the United States at Sanofi-Aventis as Vice-President Global Marketing. He was General Manager of Aventis AB in Sweden until he moved to the biotech industry in 2004. He then joined Tigenix NV, a Belgian biomedical company active in the field of Regenerative Medicine as Chief Commercial Officer. Heico holds a Medical Degree from the VU University Amsterdam and an executive MBA.
Prof. Dr. Yigal Pinto, MD
Chief Scientific Officer - Yigal Pinto was trained as a cardiologist at the University of Groningen in the Netherlands and he holds a PhD from the same university. He is also trained in molecular biology and genetics of the heart at Harvard Medical School, Boston (USA) and at the Max Delbruck Center for Molecular Medicine, Berlin (Germany). His main interest is the molecular genetics of heart failure. From 2001-2007 he was staff cardiologist at the University of Maastricht and in 2005 he was appointed as Full Professor of Cardiology. He discovered the heart failure biomarker galectin-3. In 2008 he moved to the AMC in Amsterdam to become the scientific director of the Heart Center. Yigal is an established investigator of the Netherlands Heart Foundation.
Chief Financial Officer - Having more than 25 years of experience in financial management from large enterprises to venture funds and small technology companies, Marlon acts as part time CFO for Mirnext BV. From 1999 to 2004 Marlon acted as CFO for Life Science Partners assisting in the establishment of Funds I and II. During 2005 Marlon established Finmar B.V. a boutique financial advisory and management service for SMEs in the health and medical sectors. Marlon provides financial planning, tax and strategic support for SMEs in the early phases. Having experience of sitting on both sides of the risk capital table Marlon provides critical support in raising risk capital investments. Marlon holds a degree in Business Economy from the Erasmus University.